The economic costs of dementia in Korea, 2002

  title={The economic costs of dementia in Korea, 2002},
  author={Guk-Hee Suh and Martin Knapp and Cheol-Joong Kang},
  journal={International Journal of Geriatric Psychiatry},
To estimate the economic costs of dementia in 2002 using an economic evaluation model for dementia care. 
The personal cost of dementia care in Japan: A comparative analysis of residence types
This work aimed to quantify the personal economic burden of dementia care in Japan according to residence type and to estimate the number of elderly people affected by dementia in Japan.
The worldwide economic impact of dementia 2010
The main cost drivers in dementia: a systematic review
Because of the increasing prevalence of dementia worldwide, combined with limited healthcare expenditures, a better understanding of the main cost drivers of dementia in different care settings is
Economic cost of dementia patients according to the limitation of the activities of daily living in Korea
There are few reports that have estimated the total economic cost of dementia, particularly according to the limitation in the activities of daily living (ADL) in Korea, but the impact on the economy is likely to be significant.
Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea.
  • G. Suh
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2009
It is suggested that the use of galantamine may be a cost-effective use of Korean national health-care resources, considering the gross domestic product per capita of US$21,695 in 2007.
Methodological considerations in cost of illness studies on Alzheimer disease
The review showed that cost studies adopted different approaches to estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies, and closer agreement among researchers on the methodological principles of cost Studies would be desirable.
Health Care Service Utilization of Dementia Patients before and after Institutionalization: A Claims Data Analysis
Institutional dementia care seems to be associated with an increased demand for supportive services but not necessarily for specialized medical care.
The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia
The RUD instrument appears to accurately estimate the amount of informal care provided by caregivers to dementia patients, with high agreement between diaries and recall estimates.
How Caregivers of People With Dementia Search for Dementia-Specific Information on the Internet: Survey Study
The internet use by caregivers of people with dementia in Greece within the previous 3 months was associated with variables such as age, education, occupation, kinship, years of care, and self-reported impact on physical and social health.


A review of the epidemiological transition in dementia — cross‐national comparisons of the indices related to Alzheimer's disease and vascular dementia
  • G. Suh, A. Shah
  • Medicine, Political Science
    Acta psychiatrica Scandinavica
  • 2001
Researchers examined temporal changes in the prevalence of dementia and associated factors in patients with known or suspected dementia over a 10-year period to examine whether these changes are driven by age, sex, or both.
Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding
To review the economic cost of Alzheimer's disease, to determine the level of research expenditure directed at this illness and to make comparisons with cancer, stroke and heart disease.
Costs to society of family caregiving for patients with end-stage Alzheimer's disease.
  • H. Prigerson
  • Psychology
    The New England journal of medicine
  • 2003
The cost of Alzheimer's disease is increasing at an alarming rate, and with that increase comes a dramatic upsurge in the cost of this disease to society.
A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline
To measure rates of decline in cognition and function in patients with Alzheimer's disease and to investigate their accelerating risk factors in Korea, a large number of patients with AD are diagnosed with AD.
Mortality in Alzheimer's disease: a comparative prospective Korean study in the community and nursing homes
To test a hypothesis that Alzheimer's disease (AD) patients in nursing homes have higher mortality rate than do AD patients cared for at home and to investigate the predictors of mortality in AD.
The economic cost of senile dementia in the United States, 1985.
This paper attempts to estimate various costs associated with the care of senile dementia, based on available secondary data, using the direct cost and indirect cost approach and avoided double counting to identify the additional economic costs due to seniles dementia.
The economic and social cost of dementia in Ireland
The critical role of carers in maintaining people with dementia in their own home is reflected in the results showing that family care accounts for almost 50% of the overall resource burden, based on an opportunity cost valuation of carer time.
Costs of dementia and dementia care: a review
The main result of the present study is that the costs of dementia care differ considerably in the literature, one important reason for this variability was that the number of included cost categories vary, leading to a wide range of costs.
Alzheimer's Disease Under Managed Care: Implications from Medicare Utilization and Expenditure Patterns
BACKGROUND: Little information is available about the costs, utilization patterns, and the delivery system used by Medicare beneficiaries with chronic illnesses. This information will become
Economic considerations in the treatment and management of Alzheimer's disease.
  • G. Schumock
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1998
The available economic studies indicate that, when used appropriately, cholinesterase inhibitors improve outcomes and reduce costs for patients with mild to moderate AD.